

**SomaLogic believes in creating a world where everyone can routinely monitor health and accurately diagnose, effectively treat, and proactively prevent disease.**

## ABOUT US

SomaLogic was founded in 2000 by Larry Gold, with the goal of improving the quality of life of every individual by transforming how health was assessed and managed, based on the precise measurement of changes in the body's proteins.

## WHY PROTEINS?

Proteins (e.g., enzymes, hormones, antibodies, drug receptors, etc.) give our cells structure, guide development, allow the body to move, help fight infection, transport molecules such as oxygen, and regulate complex systems such as blood sugar and mood. The levels of proteins within various parts of the body are constantly changing in response to factors such as diet, aging, drug treatments, microorganisms, and stress. These changes in protein levels provide meaningful insights into a person's state of health and wellness at any specific time and can rapidly determine whether health interventions are working.



## NOTABLE FACTS

- NASDAQ: SLGC
- Based in Boulder, Colorado
- Larry Gold, Ph.D., Founder
- Roy Smythe, M.D., Chief Executive Officer
- >200 employees worldwide
- >700 issued and pending patents
- >350 scientific publications from SomaLogic and third-party users

## THE SOMASCAN® PLATFORM TECHNOLOGY

SomaLogic alone has met the challenge of protein measurement, both in a single moment and repeatedly over time. Our proprietary SomaScan® Assay is the only technology that can measure broadly (over 7000 proteins simultaneously), deeply (high- and low-abundance proteins), and rapidly (high throughput) in a small biological sample volume.

SomaLogic has worked with leading academic institutions and biobanks around the world to apply our SomaScan Platform technology to over 500,000 samples to date, assembling the world's largest database of protein measurements and related clinical outcomes data. We use sophisticated machine learning and bioinformatics capabilities to transform this massive collection of data into quantitative risk assessments and reliable physiological, lifestyle and disease insights across many different human diseases and conditions. We also make our technology available to academic and biopharmaceutical researchers to accelerate biomarker discovery, diagnostics development, drug discovery and development, and health management.

**WEBSITE** [www.somallogic.com](http://www.somallogic.com)  
**TWITTER** [www.twitter.com/somallogic](http://www.twitter.com/somallogic)  
**LINKEDIN** [www.linkedin.com/company/somallogic](http://www.linkedin.com/company/somallogic)  
**FACEBOOK** [www.facebook.com/SomaLogicInc](http://www.facebook.com/SomaLogicInc)  
**CONTACT** [mediacontact@somallogic.com](mailto:mediacontact@somallogic.com)



## SELECTED PUBLICATIONS

The full list of over 350 peer-reviewed publications by SomaLogic and third-party users of SomaLogic's technology can be viewed at <https://somallogic.com/technology/publications/>

Pietzner, M *et al.* (2021) "Mapping the proteo-genomic convergence of human diseases." *Science*: eabj1541. <https://www.doi.org/10.1126/science.abj1541>

Williams, SA *et al.* (2019) "Plasma protein patterns as comprehensive indicators of health." *Nature Medicine* 25: 1851-1857. <https://doi.org/10.1038/s41591-019-0665-2>

Lehallier, B *et al.* (2019) "Undulating changes in human plasma proteome profiles across the lifespan." *Nature Medicine* 25: 1843-1850. <https://doi.org/10.1038/s41591-019-0673-2>

Emilsson, V *et al.* (2018) "Co-regulatory networks of human serum proteins link genetics to disease." *Science* 361(6404): 769-773. <https://doi.org/10.1126/science.aag1327>

Sun, BB *et al.* (2018) "Genomic atlas of the human plasma proteome." *Nature* 558: 73-79. <https://doi.org/10.1038/s41586-018-0175-2>

Benson, MD *et al.* (2018) "Genetic architecture of the cardiovascular risk proteome." *Circulation* 137(11): 1158-1172. <https://doi.org/10.1161/CIRCULATIONAHA.117.029536>

Williams, SA *et al.* (2018) "Improving assessment of drug safety through proteomics: early detection and mechanistic characterization of the unforeseen harmful effects of Torcetrapib." *Circulation* 137(10): 999-1010. <https://doi.org/10.1161/CIRCULATIONAHA.117.028213>

Ngo, D *et al.* (2016) "Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease." *Circulation* 134(4): 270-285. <https://doi.org/10.1161/circulationaha.116.021803>

Ganz, P *et al.* (2016) "Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease." *Journal of the American Medical Association* 315(23): 2532-2541. <https://doi.org/10.1001/jama.2016.5951>